scholarly journals Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada

2018 ◽  
Vol 181 (6) ◽  
pp. 803-815 ◽  
Author(s):  
Lee Mozessohn ◽  
Matthew C. Cheung ◽  
Saber Fallahpour ◽  
Tripat Gill ◽  
Asmaa Maloul ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Real World ◽  
The Real ◽  
Blast Count ◽  
Acute Myeloid

Microsatellite analysis in acute myeloid leukaemia evolving from myelodysplastic syndrome

2001 ◽  
Vol 112 (1) ◽  
pp. 248-249 ◽  
Author(s):  
Werner Olipitz ◽  
Gernot P. Tilz ◽  
Christine Beham-Schmid ◽  
Christa Eibinger ◽  
Petra Kerzina ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Microsatellite Analysis ◽  
Acute Myeloid

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high‐risk myelodysplastic syndrome

2019 ◽  
Vol 102 (3) ◽  
pp. 218-226
Author(s):  
Marie Warny ◽  
Jens Helby ◽  
Henrik Sengeløv ◽  
Børge G. Nordestgaard ◽  
Henrik Birgens ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Telomere Length ◽  
Mononuclear Cell ◽  
Bone Marrow Mononuclear Cell ◽  
Acute Myeloid

Myelodysplastic Syndrome, Myeloid Leukaemia of Down Syndrome, and Juvenile Myelomonocytic Leukaemia

2020 ◽  
pp. 134-141
Author(s):  
Henrik Hasle ◽  
Charlotte M. Niemeyer
Keyword(s):  
Bone Marrow ◽  
Down Syndrome ◽  
Stem Cell ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Clinical Characteristics ◽  
Bone Marrow Failure ◽  
Signal Pathways ◽  
Acute Myeloid

Myeloid malignancies in children are divided into acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukaemia (JMML), and the myeloid leukaemia of Down syndrome (ML-DS). Predisposing genetic conditions are common in MDS. Differentiating MDS from inherited bone marrow failure or AML may be challenging. Therapy consists of observation, immunosuppression, or stem-cell transplantation (SCT). Germline and somatic mutations deregulating the Ras/MAPK signal pathways are key initiating events in JMML. Genetics in JMML defines clinically relevant subgroups and indications for SCT. ML-DS presents with unique clinical characteristics and responds favourably to reduced doses of AML chemotherapy; however, relapse is often refractory to therapy.

Sign in / Sign up

Export Citation Format

Share Document